A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

Exclusion Criteria

• •History of any clinically important disease or disorder which, in the opinion of the Principal Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
• •History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• •History of chest irradiation, fibrosis, malignancy, surgical procedure, trauma or liver disease.
• •Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
• •Evidence of active tuberculosis or Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection.
• •Abnormal vital signs or clinically important abnormalities in rhythm.
• •Current smokers, known or suspected history of alcohol, drug abuse or caffeine intake.
• •History of severe allergy/hypersensitivity.
• •Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the Screening Visit.
• •Participants who are vegans or have dietary restrictions.
• •Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.